Hologic, Inc. $HOLX Shares Bought by Perbak Capital Partners LLP

by · The Markets Daily

Perbak Capital Partners LLP grew its position in Hologic, Inc. (NASDAQ:HOLX – Free Report) by 104.0% in the third quarter, HoldingsChannel reports. The institutional investor owned 20,694 shares of the medical equipment provider’s stock after purchasing an additional 10,548 shares during the period. Perbak Capital Partners LLP’s holdings in Hologic were worth $1,397,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Hologic by 10.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,776 shares of the medical equipment provider’s stock worth $2,395,000 after acquiring an additional 3,520 shares during the last quarter. Empowered Funds LLC grew its position in shares of Hologic by 27.7% in the first quarter. Empowered Funds LLC now owns 17,494 shares of the medical equipment provider’s stock valued at $1,081,000 after purchasing an additional 3,790 shares during the last quarter. Fox Run Management L.L.C. purchased a new position in shares of Hologic during the 2nd quarter worth approximately $246,000. Los Angeles Capital Management LLC acquired a new position in shares of Hologic during the 2nd quarter worth approximately $454,000. Finally, Allworth Financial LP raised its position in shares of Hologic by 120.3% during the 2nd quarter. Allworth Financial LP now owns 1,511 shares of the medical equipment provider’s stock worth $98,000 after purchasing an additional 825 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on HOLX. Argus cut Hologic from a “buy” rating to a “hold” rating in a report on Monday, January 12th. Evercore cut Hologic from an “outperform” rating to an “in-line” rating and cut their price target for the stock from $79.00 to $78.00 in a report on Monday, January 5th. Weiss Ratings restated a “hold (c)” rating on shares of Hologic in a research report on Wednesday, January 28th. Finally, BNP Paribas Exane cut Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price objective for the company. in a research report on Friday, November 21st. Two equities research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Hologic presently has an average rating of “Hold” and a consensus target price of $78.42.

View Our Latest Stock Analysis on HOLX

Hologic Price Performance

HOLX stock opened at $75.12 on Friday. The stock has a market capitalization of $16.77 billion, a price-to-earnings ratio of 31.30, a price-to-earnings-growth ratio of 2.24 and a beta of 0.73. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $75.75. The stock’s fifty day simple moving average is $75.13 and its 200-day simple moving average is $72.64.

Hologic (NASDAQ:HOLX – Get Free Report) last released its earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 EPS for the quarter, missing the consensus estimate of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The business had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the previous year, the company posted $0.87 earnings per share. The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. Equities research analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Company Profile

(Free Report)

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.

Featured Articles

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX – Free Report).